Biotech Startups

HTGF is a multi-stage venture capital platform investing in early-stage technology founders across Deep Tech, Life Sciences, and Digital Tech from pre-seed to growth stage. The firm backs German and European companies with capital, network, and expertise to help build global technology champions.

3 investors

Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.

3 investors

Humedics develops LiMAx, a breath analysis technology for rapid and precise measurement of liver function, enabling doctors to make tailored treatment decisions at the bedside. The company serves healthcare providers and hospitals in diagnostic medicine.

3 investors

3 investors

Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins. The company operates in drug discovery, using its proprietary Hyku platform to address challenges such as selectivity, druggability, and resistance in disease targets.

3 investors

IBI-Ag develops selective bio-insecticides based on single domain antibody technology that target specific proteins in insect pests, aimed at helping farmers protect crops with minimal harm to workers, consumers, and the environment. The company operates in the agricultural biotechnology and biological pest control sector.

3 investors

3 investors

Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

3 investors

IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases. The company aims to positively impact the health of 2.5 billion people by the end of the decade.

3 investors

iFAST Diagnostics develops rapid antimicrobial susceptibility testing (AST) technology that delivers susceptibility test results in under 3 hours, significantly faster than the standard 40-hour process. The company serves clinical laboratories and hospitals to help combat antimicrobial resistance.

3 investors

A biotechnology company, founded in 2013, developing regenerative medicine technologies including methods to differentiate stem cells into cardiovascular cells and hydrogel-particle-based layering techniques. Its foundational technologies originate from academic research in Japan.

3 investors

Ikarovec is a biotech company focused on developing treatments for retinal diseases affecting vision. The company combines clinical expertise with preclinical research capabilities.

3 investors

iLabService builds real-time LabOps infrastructure that combines lab management software, AIoT hardware, and local response systems to turn lab-floor signals into audit-ready operating evidence for regulated laboratories. It serves pharma, biotech, CRO/CDMO, testing, and enterprise R&D teams for monitoring, risk response, incident reconstruction, and QA/EHS/compliance workflows.

3 investors

Imagenomix develops AI-powered genomic diagnostics for cancer patients, using computational pathology to predict genetic alterations from tissue imagery. The company serves oncologists and pathologists seeking precision medicine insights for clinical decision-making.

3 investors

Imio makes Re-Gen, a freeze-dried microbial powder applied to crop residue for row crops such as corn, helping farmers unlock NPK nutrient value and increase yields. The product is aimed at agricultural growers seeking fertilizer savings and higher output per acre.

3 investors

Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.

3 investors

Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules. The company pursues partnerships, collaborations, and licensing opportunities to expand the therapeutic applications of its technology.

3 investors

InBioMotion offers a biomarker test that analyzes MAF gene levels to assess prognosis and guide personalized bisphosphonate treatment in early breast cancer patients. The test helps oncologists reduce relapse risk and improve survival outcomes through precision medicine approaches.

3 investors

Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.

3 investors

Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2. The company focuses on drug development for patients with advanced and resistant cancers.

3 investors

INDIGO Biosciences is a life sciences company led by professionals with expertise in life sciences, business management, and operations.

3 investors

InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers. The company built proprietary platforms — Membrane Interactomics (MInt) for target discovery, ARRIS for proximity modalities using multi-specific antibody technology, and internal antibody discovery and engineering — to identify targets and design therapeutic molecules.

3 investors

Ingenix builds an AI "Reasoning Engine" using an approach it calls Modality Fusion to integrate biological data across modalities and scales. It targets R&D decisions affecting clinical efficacy and safety outcomes in drug development, serving biotech and pharmaceutical research.

3 investors

Inherent Biosciences develops clinical diagnostic solutions using epigenetics and AI to address complex healthcare concerns. The company is built by a team of molecular biologists, data scientists, and healthcare providers.

3 investors